Introduction {#sec1-1}
============

The INDIAN (023) blood group system currently consists of 4 antigens, namely, In (a), In (b), In3, and In4. Of these, In (a) occurs in a low frequency of about 3% in Indians.\[[@ref1]\] It was less uncommon among the Arabs (11.8%) and Iranians (10.6%) tested.\[[@ref2]\] The Salis antibody to a high-frequency antigen (HFA), found earlier in a Pakistani patient, was directed to the antigen that turned out to be antithetical to In(a), hence was named as In(b).\[[@ref3]\] The INDIAN blood group system was further expanded in the year 2007 when two more antigens, namely, INFI and INJA were recognized as part of the system. Both these antigens were HFA. Of these, the INFI was detected among the Moroccans, while the INJA was found among the individuals who had their origin in the Indian subcontinent.\[[@ref4]\] These 4 antigens of the INDIAN (023) blood group system are now known by their numerical terms IN: 001, IN: 002, IN: 003, and IN: 004 assigned by the ISBT.\[[@ref5]\]

Antibodies to INDIAN blood group antigens result in direct agglutination of red blood cells (RBCs) in saline medium but react stronger by the indirect antiglobulin test (IAT).\[[@ref1]\] The antigens of the system are sensitive to proteolytic enzymes like papain\[[@ref1]\] and chemicals like 2-aminoethyl isothiouronium bromide (AET).\[[@ref6]\] Such properties may provide hints in the identification of the antibodies. We encountered such an antibody to HFA that we thought, may belong to the INDIAN blood group system, so we investigated the case from that angle.

Materials and Methods {#sec1-2}
=====================

The case {#sec2-1}
--------

A 40-year-old female had a history of seven pregnancies but never received transfusion. She was hospitalized with continuous bleeding p.v. due to the uterine tumor. In the face of anemia, with the hemoglobin level of 8 g/dL, patient was planned for transfusion. Her blood specimen was referred to arrange blood units in case the patient required a transfusion during/after surgery. The pretransfusion compatibility tests were initiated. Antibody screening test (AST) was positive, and the cross matching with several blood units was incompatible. Hysterectomy was performed without blood transfusion. The standard serological methods were employed in pretransfusion compatibility tests and other serological workups. For molecular genetics study, the DNA was extracted from the patient\'s sample. The exons of the hemopoietic isoform of the *CD44* gene were amplified by polymerase chain reaction and sequenced.

Results {#sec1-3}
=======

The patient was grouped as A1B, RhD+ with a positive AST. The direct antiglobulin test and the autocontrol tests were negative, indicating the presence of alloantibody in her serum. The antibody strongly agglutinated the RBCs in saline/low ionic strength solution (LISS) phase at room temperature and by LISS-IAT at 37°C. The antibody showed uniform hemagglutination strength on over 50 random samples and 11 commercial RBCs panel. The antibody failed to react with the RBCs pretreated with papain enzyme and the AET. In accordance with these observations, the patient\'s RBCs were tested and gave positive reaction with anti-In(b), thus ruling out the specificity to this HFA. After initial serological investigations in our laboratory, her blood specimen was referred to IBGRL, UK to rule out/rule in the specificity to other known antigens of the INDIAN blood group system, namely, In:3 and In4. As the antibody had reacted with red cells lacking In3 and In4 antigens, its specificity against these antigens of the INDIAN blood groups was ruled out. In addition, the antibody had reacted with RBCs of several "*null*"phenotypes, including Gerbich-null, Rh-null,-D-/-D-, MkMk, Fy(a-b-), Gy(a-), and K0, thus ruling out its specificity to the hitherto known HFAs. However, the RBCs of the Lu (a-b-)/In (Lu) type showed a depressed reactivity with the antibody. Furthermore, the antibody was not inhibited by the soluble proteins of DAF (chromer) and Yt(a) blood group antigens so its specificity to those HFAs was ruled out. The antibody did not agglutinate RBCs if they were treated with enzyme chymotrypsin, though it reacted with RBCs treated with trypsin or dithiothreitol.

The patient\'s RBCs were typed positive with antisera to a number of papain-sensitive and papain-resistant HFAs, including In(b), In3, IN4, Kn(a), McC(a), Yt(a), U, Vel, En(a), Kp(b), Js(b), Wr(b), Ge, CD99. These findings had corroborated in ruling out the specificity of the patient\'s alloantibody to these antigens.

The genomic analysis revealed the patient to be IN \* B (IN \*02) homozygous. In exon 5 of *CD44*, a *novel* homozygous missense mutation c. 449G\>A was revealed, encoding p. Arg150His amino acid substitution at the protein level. This mutation resulted in a lack of expression of a *novel* HFA to which we have proposed the name INRA after the patient and have obtained the ISBT numerical term as IN: 005. The INRA gene sequence has been allocated GenBank accession number KX639826. Besides this, in exon 2 of the *CD44*, a *novel* homozygous synonymous (silent) mutation c.255C\>T was observed in a codon for p. His85. However, for the moment, it remains an enigmatic entity.

Discussion {#sec1-4}
==========

The antibody to HFAs makes it difficult to find a compatible blood for transfusion. It poses a problem in identification of its serological specificity as well and also gives difficulties in finding the "antigen-negative" blood unit for transfusion. Sometimes, the properties of the corresponding antigen like sensitivity to proteolytic enzymes or certain chemicals may provide a clue to the presumptive specificity of the antibody. In the present case, the antibody showed direct agglutination of red cells in saline/LISS medium and that, it did not agglutinate the RBCs pretreated with enzyme/AET thus indicating the specificity to the HFA of the INDIAN blood group system.\[[@ref1][@ref6]\] As a rule, an alloantibody is developed in a person who lacks the corresponding antigen. In other words, the specificity of an alloantibody is ruled out, if the antibody producer is positive for that antigen. In a similar note, if an antibody has reacted with the RBCs devoid of an antigen, the specificity to that antigen is ruled out. This maneuver in the identification of antibodies may need an exhaustive rare red cells panel that lacks the HFAs. Besides, it requires the rare antisera to HFA to be tested. In the present study, the patient\'s red cells were typed positive with antisera to the HFAs, thus ruling out the specificity of her alloantibody to those antigens. Besides, her antibody had reacted with RBCs lacking the HFAs further ruling out its specificity to hitherto known HFA.

The In(a)/In(b) antigens are weakly expressed on red cells with Lu(a-b-)/In(Lu) phenotype.\[[@ref7][@ref8]\] The antibody in the present case showed depressed reactivity with such RBCs. This observation hinted that the antigen defined by the patient\'s antibody may belong to the INDIAN blood group system. The genetic sequence studied on hemopoietic isoform of the *CD44* that carries the INDIAN blood group antigens,\[[@ref7]\] revealed a *novel* homozygous missense mutation c.449G\>A in exon 5, encoding p. Arg150His amino acid substitution at the protein level and that, this mutation resulted in a lack of expression of a novel HFA in the INDIAN (023) blood group system. The name INRA, given by us to this antigen, was ratified as the *novel* antigen with its numerical term as IN005 by the ISBT.

The *CD44* gene is located on chromosome 11 at position p13.\[[@ref7]\] The In (a)/In (b) polymorphism results from the single base change in exon 2 of *CD44* gene that substitutes one amino acid, from Pro to Arg at position 46 of the *CD44* protein.\[[@ref9]\] The common allele, *In(b)*, has G252 and encodes Arg46 while the rare allele *In(a)* has C252 and encodes Pro46. This has resulted from a single mutation G \> C in *CD44* at position 252.\[[@ref9]\] A lack of IN3 and IN4 results from homozygosity for mutations encoding H85Q and T163K in the *CD44* gene.\[[@ref4]\] In the present case, the patient lacked a *novel* HFA (INRA, In5) that has resulted from homozygous mutation 449G\>A in exon 5 of the *CD44* gene encoding an amino acid change Arg150His at the protein level.

Conclusion {#sec1-5}
==========

The antibody to the enzyme sensitive hitherto unknown HFA was investigated. Serological and molecular studies have provided evidence for a *novel* antigen in the INDIAN (023) blood group system. The new HFA named INRA, was assigned the numerical term In: 005 by the ISBT.
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